Literature DB >> 27482174

Chromoendoscopy and Dysplasia Surveillance in Inflammatory Bowel Disease: Past, Present, and Future.

Steven Naymagon1, Thomas A Ullman1.   

Abstract

The evidence supporting the practice of dysplasia surveillance in inflammatory bowel disease (IBD) has remained sparse, and optimal detection strategies are still lacking. These issues, added to the declining incidence of dysplasia in IBD, have led to much debate over the diagnosis and management of dysplasia. White-light endoscopy with targeted and random biopsies remains the technique of choice for most practicing gastroenterologists. However, during the past decade, a surge of literature has questioned the efficacy of this strategy. Simultaneously, chromoendoscopy has emerged as an alternative, and perhaps superior, technique that has been included in some society guidelines. Nevertheless, many issues remain unclear, such as the best way to implement chromoendoscopy into everyday practice, whether there are any outcome benefits that can be attributed to the use of chromoendoscopy, and, perhaps most importantly, how to manage dysplasia uncovered by this and other advanced techniques. In this article, we discuss the various techniques currently available for dysplasia surveillance in IBD, with a focus on chromoendoscopy. Additionally, we highlight the overarching issues of setting appropriate endpoints and individualizing the care of patients with long-standing colitis.

Entities:  

Keywords:  Chromoendoscopy; Crohn’s disease; dysplasia; inflammatory bowel disease; ulcerative colitis

Year:  2015        PMID: 27482174      PMCID: PMC4962681     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  68 in total

1.  Chromoendoscopy with methylene blue and the risk of DNA damage.

Authors:  L J Hardie; J R Olliver; C P Wild; S Dexter; P Sahay
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

2.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study.

Authors:  Maria Pellisé; Maria López-Cerón; Cristina Rodríguez de Miguel; Mireya Jimeno; Michel Zabalza; Elena Ricart; Montserrat Aceituno; Glòria Fernández-Esparrach; Angels Ginès; Oriol Sendino; Miriam Cuatrecasas; Josep Llach; Julián Panés
Journal:  Gastrointest Endosc       Date:  2011-07-29       Impact factor: 9.427

5.  Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data.

Authors:  Urpo Nieminen; Airi Jussila; Stig Nordling; Harri Mustonen; Martti A Färkkilä
Journal:  Int J Cancer       Date:  2013-07-16       Impact factor: 7.396

6.  Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences.

Authors:  Frank J C van den Broek; Pieter C F Stokkers; Johannes B Reitsma; Robin P B Boltjes; Cyriel Y Ponsioen; Paul Fockens; Evelien Dekker
Journal:  Am J Gastroenterol       Date:  2011-03-22       Impact factor: 10.864

7.  Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis.

Authors:  Ralf Kiesslich; Martin Goetz; Katharina Lammersdorf; Constantin Schneider; Juergen Burg; Manfred Stolte; Michael Vieth; Bernhard Nafe; Peter R Galle; Markus F Neurath
Journal:  Gastroenterology       Date:  2007-01-31       Impact factor: 22.682

8.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial.

Authors:  James F Marion; Jerome D Waye; Daniel H Present; Yuriy Israel; Carol Bodian; Noam Harpaz; Mark Chapman; Steven Itzkowitz; Adam F Steinlauf; Maria T Abreu; Thomas A Ullman; James Aisenberg; Lloyd Mayer
Journal:  Am J Gastroenterol       Date:  2008-09       Impact factor: 10.864

10.  Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions.

Authors:  F J C van den Broek; P Fockens; S van Eeden; J B Reitsma; J C H Hardwick; P C F Stokkers; E Dekker
Journal:  Gut       Date:  2008-03-26       Impact factor: 23.059

View more
  4 in total

1.  How Dye May Prevent Dying from Cancer: Perceiving Imperceptible Dysplasia in Inflammatory Bowel Disease.

Authors:  Sara M Lewin; Kwun Wah Wen; Fernando S Velayos; Uma Mahadevan; Kendall R Beck
Journal:  Dig Dis Sci       Date:  2019-01       Impact factor: 3.199

Review 2.  Role of endoscopy in inflammatory bowel disease.

Authors:  Shishira Bharadwaj; Neeraj Narula; Parul Tandon; Mohammad Yaghoobi
Journal:  Gastroenterol Rep (Oxf)       Date:  2018-03-09

3.  Validation of epigenetic markers to identify colitis associated cancer: Results of module 1 of the ENDCAP-C study.

Authors:  Andrew D Beggs; Samir Mehta; Jonathan J Deeks; Jonathan D James; Germaine M Caldwell; Mark P Dilworth; Joanne D Stockton; Daniel Blakeway; Valerie Pestinger; Alexandra Vince; Phillipe Taniere; Tariq Iqbal; Laura Magill; Glenn Matthews; Dion G Morton
Journal:  EBioMedicine       Date:  2018-11-22       Impact factor: 8.143

Review 4.  Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications.

Authors:  Bishnu P Joshi; Thomas D Wang
Journal:  Contrast Media Mol Imaging       Date:  2018-08-27       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.